Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 11/2014

01-11-2014 | Brief report

Association between genetic variant in hsa-miR-146a gene and prostate cancer progression: evidence from Serbian population

Authors: Zorana Z. Nikolić, Dušanka Lj. Savić Pavićević, Vinka D. Vukotić, Saša M. Tomović, Snežana J. Cerović, Nataša Filipović, Stanka P. Romac, Goran N. Brajušković

Published in: Cancer Causes & Control | Issue 11/2014

Login to get access

Abstract

Purpose

Two previous studies of association between rs2910164 in miR-146a gene and prostate cancer (PCa) risk have provided opposing results. Furthermore, no evidence of association of this SNP with standard prognostic parameters of PCa progression was obtained in mentioned studies. The main aim of this study was to evaluate the possible association between PCa onset and progression to a more aggressive form, since it has not been assessed in a population of European descent.

Methods

In this study, 286 samples of peripheral blood were obtained from patients with PCa, while the control group comprised 199 volunteers derived from general population who gave samples of buccal swabs. For individuals diagnosed with PCa clinicopathological characteristics including serum prostate-specific antigen level at diagnosis, Gleason score (GS), and clinical stage were determined. Genotyping of rs2910164 was performed using Taqman® SNP Genotyping Assay. Analysis of SNP association was done using PLINK and SNPStats software.

Results

rs2910164 showed no association with PCa risk. Nevertheless, heterozygous genotype was found to be associated with higher GS, as well as with the presence of distant metastases. rs2910164 was also shown to be associated with cancer aggressiveness (p = 0.0067; ORGC = 2.22, 95 %CI 1.24–3.97; ORCC = 0.47, 95 %CI 0.13–1.68).

Conclusions

Our results show no evidence of association between rs2910164 and PCa risk in Serbian population. Conversely, this variant was found to be associated with PCa aggressiveness.
Literature
1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN. Int J Cancer 127(12):2893–2917PubMedCrossRef
2.
Alshalalfa M, Bader GD, Goldenberg A, Morris Q, Alhajj R (2012) Detecting microRNAs of high influence on protein functional interaction networks: a prostate cancer case study. BMC Syst Biol 6:112PubMedCrossRefPubMedCentral
3.
4.
Shenouda SK, Alaahri SK (2009) MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 28:369–378PubMedCrossRef
5.
Xu B, Feng NH, Li PC et al (2010) A functional polymorphism in pre-miR-146a gene is associated with prostate cancer risk and mature miR-146a expression in vivo. Prostate 70(5):467–472PubMed
6.
George GP, Gangwar R, Mandal RK, Sankhwar SN, Mittal RD (2011) Genetic variation in microRNA genes and prostate cancer risk in North Indian population. Mol Biol Rep 38(3):1609–1615PubMedCrossRef
7.
Medeiros RM, Morais A, Vasconcelos A et al (2002) Outcome in prostate cancer: association with endothelial nitric oxide synthase Glu-Asp298 polymorphism at exon 7. Clin Cancer Res 8(11):3433–3437PubMed
8.
Purcell S, Neale B, Todd-Brown K et al (2007) PLINK: a toolset for whole-genome association and population-based linkage analysis. Am J Hum Genet 81(3):559–575PubMedCrossRefPubMedCentral
9.
Solé X, Guinó E, Valls J, Iniesta R, Moreno V (2006) SNPstats: a web tool for the analysis of association studies. Bioinformatics 22(15):1928–1929PubMedCrossRef
10.
11.
Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A (2008) Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci USA 105(20):7269–7274PubMedCrossRefPubMedCentral
12.
Pastrello C, Polesel J, Della Puppa L, Viel A, Maestro R (2010) Association between hsa-mir-146a genotype and tumor age-of-onset in BRCA1/BRCA2-negative familial breast and ovarian cancer patients. Carcinogenesis 31(12):2124–2126PubMedCrossRef
13.
Yue C, Wang M, Ding B et al (2011) Polymorphism of the pre-miR-146a is associated with risk of cervical cancer in a Chinese population. Gynecol Oncol 122(1):33–37PubMedCrossRef
14.
Guo H, Wang K, Xiong G et al (2010) A functional varient in microRNA-146a is associated with risk of esophageal squamous cell carcinoma in Chinese Han. Fam Cancer 9(4):599–603PubMedCrossRef
15.
Xu T, Zhu Y, Wei QK et al (2008) A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis 29(11):2126–2131PubMedCrossRef
16.
Zeng Y, Sun QM, Liu NN et al (2010) Correlation between pre-miR-146a C/G polymorphism and gastric cancer risk in Chinese population. World J Gastroenterol 16(28):3578–3583PubMedCrossRefPubMedCentral
17.
Jazdzewski K, Liyanarachchi S, Swierniak M et al (2009) Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci USA 106(5):1502–1505PubMedCrossRefPubMedCentral
18.
19.
Xu B, Wang N, Wang X et al (2012) MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer. Prostate 72(11):1171–1178PubMedCrossRef
Metadata
Title
Association between genetic variant in hsa-miR-146a gene and prostate cancer progression: evidence from Serbian population
Authors
Zorana Z. Nikolić
Dušanka Lj. Savić Pavićević
Vinka D. Vukotić
Saša M. Tomović
Snežana J. Cerović
Nataša Filipović
Stanka P. Romac
Goran N. Brajušković
Publication date
01-11-2014
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 11/2014
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-014-0452-9

Other articles of this Issue 11/2014

Cancer Causes & Control 11/2014 Go to the issue

Original paper

The effect of test kit provision, and individual and family education on the uptake rates of fecal occult blood test in an Asian population: a randomized controlled trial

Original paper

Cognitive impairment and cancer mortality: a biological or health care explanation?

Original paper

Postoperative 30-day mortality in patients undergoing surgery for colorectal cancer: development of a prognostic model using administrative claims data

Original Paper

Polymorphisms in the carcinogen detoxification genes CYB5A and CYB5R3 and breast cancer risk in African American women

Original paper

Italianity is associated with lower risk of prostate cancer mortality in Switzerland

Original paper

Cholelithiasis and risk of pancreatic cancer: systematic review and meta-analysis of 21 observational studies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits